Author(s):
Kissling, Esther ; Hooiveld, Mariette ; Martinez-Baz, Ivan ; Mazagatos, Clara ; William, Naoma ; Vilcu, Ana Maria ; Kooijman, Marjolein N. ; Ilic, Maja ; Domegan, Lisa ; Machado, Ausenda ; De Lusignan, Simon ; Lazar, Mihaela ; Meijer, Adam ; Brytting, Mia ; Casado, Itziar ; Larrauri, Amparo ; Murray, Josephine L.K. ; Behillil, Sylvie ; De Gier, Brechje ; Mlinaric, Ivan ; O'Donnell, Joan ; Rodrigues, Ana Paula ; Tsang, Ruby ; Timnea, Olivia ; De Lange, Marit ; Riess, Maximilian ; Castilla, Jesus ; Pozo, Francisco ; Hamilton, Mark ; Falchi, Alessandra ; Knol, Mirjam J. ; Filipovic, Sanja Kurecic ; Dunford, Linda ; Guiomar, Raquel ; Cogdale, Jade ; Cherciu, Carmen ; Jansen, Tessa ; Enkirch, Theresa ; Basile, Luca ; Connell, Jeff ; Gomez, Veronica ; Martin, Virginia Sandonis ; Bacci, Sabrina ; Rose, Angela M.C. ; Celentano, Lucia Pastore ; Valenciano, Marta ; Kislaya, Irina ; Nunes, Baltazar
Date: 2022
Persistent ID: http://hdl.handle.net/10362/149492
Origin: Repositório Institucional da UNL
Subject(s): Epidemiology; Public Health, Environmental and Occupational Health; Virology; SDG 3 - Good Health and Well-being
Description
Funding Information: This project received funding from the European Centre for Disease Prevention and Control (ECDC) under the contract ECD.11486. Funding Information: This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673. Publisher Copyright: © 2022 European Centre for Disease Prevention and Control (ECDC). All rights reserved.
Introduction: In July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe. Aim: Using a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection. Methods: Individuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2. We measured complete primary course overall VE by vaccine brand and by time since vaccination. Results: Overall VE was 74% (95% CI: 69-79), 76% (95% CI: 71-80), 63% (95% CI: 48-75) and 63% (95% CI: 16-83) among those aged 30-44, 45-59, 60-74 and ≥ 75 years, respectively. VE among those aged 30-59 years was 78% (95% CI: 75-81), 66% (95% CI: 58-73), 91% (95% CI: 87-94) and 52% (95% CI: 40-61), for Comirnaty, Vaxzevria, Spikevax and COVID-19 Vaccine Janssen, respectively. VE among people 60 years and older was 67% (95% CI: 52-77), 65% (95% CI: 48-76) and 83% (95% CI: 64-92) for Comirnaty, Vaxzevria and Spikevax, respectively. Comirnaty VE among those aged 30-59 years was 87% (95% CI: 83-89) at 14-29 days and 65% (95% CI: 56-71%) at ≥ 90 days between vaccination and onset of symptoms. Conclusions: VE against symptomatic infection with the SARS-CoV-2 Delta variant varied among brands, ranging from 52% to 91%. While some waning of the vaccine effect may be present (sample size limited this analysis to only Comirnaty), protection was 65% at 90 days or more between vaccination and onset.
